Clinical Trials Directory

Trials / Completed

CompletedNCT05154955

A Safety and Tolerability Study of 10XB-101 Injection in Adult Subjects With Submental Fat

A Multi-Center, Randomized, Double-Blinded, Vehicle-Controlled Study of the Safety and Efficacy of 10XB-101 in Adult Subjects With Submental Fat

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
51 (actual)
Sponsor
10xBio, LLC · Industry
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Accepted

Summary

The purpose of this research study is to determine the safety and efficacy of 10XB-101 vs. vehicle (placebo) for adults with excessive submental fat (SMF).

Conditions

Interventions

TypeNameDescription
DRUG10XB-101 Solution for InjectionOne of the three concentrations of 10XB-101 will be evaluated against placebo for submental fat reduction.
DRUG10XB-101 Vehicle Solution for InjectionThis is the placebo control

Timeline

Start date
2021-10-19
Primary completion
2024-03-19
Completion
2024-03-19
First posted
2021-12-13
Last updated
2025-06-29

Locations

4 sites across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT05154955. Inclusion in this directory is not an endorsement.

A Safety and Tolerability Study of 10XB-101 Injection in Adult Subjects With Submental Fat (NCT05154955) · Clinical Trials Directory